Eiger BioPharmaceuticals Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Eiger BioPharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Eiger BioPharmaceuticals stock.
View analyst ratings for Eiger BioPharmaceuticals or view top-rated stocks.

Wall Street analysts have given Eiger BioPharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Eiger BioPharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Eiger BioPharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Eiger BioPharmaceuticals.

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) announced its earnings results on Thursday, May, 6th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.51) by $0.02. The biotechnology company earned $3.65 million during the quarter, compared to analysts' expectations of $0.97 million.
View Eiger BioPharmaceuticals' earnings history.

Eiger BioPharmaceuticals' stock was trading at $6.81 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, EIGR stock has increased by 19.1% and is now trading at $8.11.
View which stocks have been most impacted by COVID-19.

2 equities research analysts have issued 1-year target prices for Eiger BioPharmaceuticals' stock. Their forecasts range from $22.00 to $28.00. On average, they expect Eiger BioPharmaceuticals' share price to reach $25.50 in the next year. This suggests a possible upside of 214.4% from the stock's current price.
View analysts' price targets for Eiger BioPharmaceuticals or view top-rated stocks among Wall Street analysts.

Some companies that are related to Eiger BioPharmaceuticals include Coherus BioSciences (CHRS), Mesoblast (MESO), Scholar Rock (SRRK), Immunovant (IMVT), Aligos Therapeutics (ALGS), Vaxart (VXRT), Taysha Gene Therapies (TSHA), Inhibrx (INBX), iTeos Therapeutics (ITOS), CEL-SCI (CVM), Sutro Biopharma (STRO), Passage Bio (PASG), Aerie Pharmaceuticals (AERI), Tarsus Pharmaceuticals (TARS) and Talaris Therapeutics (TALS).
View all of EIGR's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Eiger BioPharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Gilead Sciences (GILD), Skyworks Solutions (SWKS), ZIOPHARM Oncology (ZIOP), Amarin (AMRN), Celldex Therapeutics (CLDX), Catalyst Pharmaceuticals (CPRX), Exelixis (EXEL), SCYNEXIS (SCYX) and Sangamo Therapeutics (SGMO).

Eiger BioPharmaceuticals trades on the NASDAQ under the ticker symbol "EIGR."

Eiger BioPharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Ameriprise Financial Inc. (13.11%), BlackRock Inc. (7.40%), Geode Capital Management LLC (1.65%), Goldman Sachs Group Inc. (1.50%), Assenagon Asset Management S.A. (1.16%) and P.A.W. Capital Corp (1.12%). Company insiders that own Eiger BioPharmaceuticals stock include Eldon C Mayer III, Evan Loh, Jeffrey S Glenn and Thomas John Dietz.
View institutional ownership trends for Eiger BioPharmaceuticals.

EIGR stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., GSA Capital Partners LLP, JPMorgan Chase & Co., Laurion Capital Management LP, Northern Trust Corp, Algert Global LLC, Citigroup Inc., and Man Group plc. Company insiders that have sold Eiger BioPharmaceuticals company stock in the last year include Eldon C Mayer III, and Evan Loh.
View insider buying and selling activity for Eiger BioPharmaceuticals or view top insider-selling stocks.

EIGR stock was acquired by a variety of institutional investors in the last quarter, including Ameriprise Financial Inc., BlackRock Inc., Renaissance Technologies LLC, Geode Capital Management LLC, Russell Investments Group Ltd., Dimensional Fund Advisors LP, Morgan Stanley, and Axiom Investment Management LLC. Company insiders that have bought Eiger BioPharmaceuticals stock in the last two years include Eldon C Mayer III, Jeffrey S Glenn, and Thomas John Dietz.
View insider buying and selling activity for Eiger BioPharmaceuticals or or view top insider-buying stocks.

Shares of EIGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EIGR stock can currently be purchased for approximately $8.11.

Eiger BioPharmaceuticals has a market capitalization of $275.34 million. The biotechnology company earns $-65,050,000.00 in net income (profit) each year or ($2.31) on an earnings per share basis.

Eiger BioPharmaceuticals employs 31 workers across the globe.

The official website for Eiger BioPharmaceuticals is www.eigerbio.com.

Eiger BioPharmaceuticals is headquartered at 2155 PARK BOULEVARD, PALO ALTO CA, 94306.

Eiger BioPharmaceuticals' mailing address is 2155 PARK BOULEVARD, PALO ALTO CA, 94306. The biotechnology company can be reached via phone at 650-272-6138 or via email at [email protected]